TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Technology #CSEStocks #SmallCaps #Investing
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea. The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–based healthcare distribution company...
http://dlvr.it/TQ5Zv8
http://dlvr.it/TQ5Zv8
Comments
Post a Comment